Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups.

Published byPaul Blankenship Modified over 8 years ago

Similar presentations

Presentation on theme: "Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups."— Presentation transcript:

1 Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups

2 Fig B. HRs with 95% CIs for duration of endogenous estrogen exposure (per 1 year increase) on disease-free survival of breast cancer by clinicopathological subgroups

3 Fig C. HRs with 95% CIs for number of children ≥4 vs. 2 on disease-free survival of breast cancer by clinicopathological subgroups

4 Fig D. HRs with 95% CIs for number of years since last birth <5 vs. ≥20 years on disease-free survival of breast cancer by clinicopathological subgroups

Download ppt "Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups."

Similar presentations

Fig. 4-1, p. 107. Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract 15. 486826/477169/465253/454771/4406110/4146.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.
Fig. 11-1, p. 359. p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.
Table 6-1, p. 161. Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
CaD TrialObservational Study All participantsNo Personal Supplements a Non-users ofCalcium +CalciumVitamin D PlaceboCaDPlaceboCaDSupplementsVitamin DOnly.

CaD TrialObservational Study All participantsNo Personal Supplements a Non-users ofCalcium +CalciumVitamin D PlaceboCaDPlaceboCaDSupplementsVitamin DOnly.
Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.

Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.
Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.

Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.
RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.

RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

Similar presentations

Ads by Google